Compare Johnson & Johnson (JNJ) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs TORM plc — how do they compare? Johnson & Johnson trades at $260.33 (market cap $618.09B), while TORM plc trades at $40.03 (market cap $4.12B). The key difference: Johnson & Johnson is far larger — about 150× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and TORM plc for 23 Days on average.
| JNJ | TRMD | |
|---|---|---|
Market Cap | $618.09B | $4.12B |
Volume | 6,050,983 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $278.43 | $41.05 |
52-Week Low | $186.00 | $19.39 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $646.37B | $4.83B |
Dividend Yield | 2.09% | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
TRMD trades at $40.19, up 3.26% today, with a bullish technical outlook from moving averages. The stock shows strong profitability with a 35.52% net income margin and attractive valuation ratios, including a P/E of 6.59. Recent earnings saw a Q4 2025 beat but Q1 and Q2 2026 misses, while Q3 2026 results are pending. A $2.40 dividend is scheduled for September 2026. Cash flow improved to a net positive $6M in 2026 from a negative $113.8M in 2025.
The outlook is positive given robust fundamentals and unanimous analyst buy ratings, though risks include spot rate volatility and insider selling. Revenue growth and dividend yield present opportunities, but investors should monitor freight rate trends and execution on future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
